RA Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

RA Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.5M	Buy	+6,804,072	New	+$23M	0.27%	52
2025 Q2	–	Sell	-4,666,667	Closed	-$7.14M	–	64
2025 Q1	$7.14M	Hold	4,666,667	–	–	0.12%	71
2024 Q4	$11.6M	Buy	+4,666,667	New	+$11.6M	0.15%	71
2023 Q4	–	Sell	-4,398,453	Closed	-$30.1M	–	63
2023 Q3	$30.1M	Hold	4,398,453	–	–	0.59%	44
2023 Q2	$45.6M	Hold	4,398,453	–	–	0.86%	34
2023 Q1	$35.6M	Hold	4,398,453	–	–	0.81%	38
2022 Q4	$69.3M	Hold	4,398,453	–	–	1.41%	24
2022 Q3	$69.2M	Hold	4,398,453	–	–	1.48%	21
2022 Q2	$61.4M	Buy	4,398,453 +2,580,645	+142%	+$36.2M	1.64%	17
2022 Q1	$31.3M	Buy	+1,817,808	New	+$24.8M	0.68%	45
2016 Q4	–	Sell	-1,547,152	Closed	-$39.6M	–	28
2016 Q3	$39.6M	Sell	1,547,152 -1,080,567	-41%	-$22.9M	4.09%	8
2016 Q2	$48.5M	Hold	2,627,719	–	–	6.72%	5
2016 Q1	$49.8M	Buy	2,627,719 +63,166	+2%	+$1.21M	6.36%	4
2015 Q4	$69.1M	Buy	+2,564,553	New	+$50M	6.84%	5

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RA Capital Management's ACRS Position: Q1 2026 in Review

RA Capital Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 6,804,072 shares worth $25.5M. The stake represents 0.27% of the portfolio and ranks #52 among its holdings. This is a return to the name: RA Capital Management previously reported a position in ACRS as recently as Q1 2025.

RA Capital Management first reported a position in ACRS in Q4 2015 and has held it in 14 quarters since. The position peaked at $69.3M in Q4 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

RA Capital Management held 6,804,072 shares of Aclaris Therapeutics worth $25.5M as of Q1 2026.
Aclaris Therapeutics was a new RA Capital Management position in Q1 2026.
Aclaris Therapeutics made up 0.27% of RA Capital Management's portfolio in Q1 2026, its #52 holding.
RA Capital Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 14 quarters since.
RA Capital Management's Aclaris Therapeutics position peaked at $69.3M in Q4 2022.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.